Indaptus Therapeutics, Inc. stock is up 18.53% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 November’s closed higher than October.
Indaptus Therapeutics, Inc. develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors.